Trip. Thanks,
of by total technologies. of across of of revenue continued the of growth both second quarter performance our to second in expanding propelled revenue We surgical record proposition $XX.X commercial XXXX. the quarter generated growth clinical activity evidence initiatives great strong We and Our the successful growing million, compared businesses, and our supporting dry eye. XX% glaucoma strong execution value displayed our saw
eye. were landmark for randomized notably, enabled clinical eyelid announce TearCare to Restasis to were success dry by endpoint. the to improving eyelid tear drug, Restasis interventional the interventional sign trial, up versus procedures procedures TBUT, objective of SAHARA, comparing enabled six-month TearCare treatment our the Most technology endpoint, controlled the superior we At break by thrilled time or technology primary of our and device
with or primary respect TearCare Disease was in Index, the to Ocular Restasis OSDI, also endpoint. symptoms non-inferior Surface to improvement subjective
the symptoms significant in XX clinically improvements at signs statistically interval. every all TearCare demonstrated As Group and importantly, of and patients endpoints measured observation
daily are and the from dry We eye foundation results procedures. clinical eye they away to treat the these help dry market about twice transform year towards rethink by lay will moving believe and once or physicians they how us and for extremely eye drops a excited prescription interventional
payers Medicare X as An access Part would the We the six-month meeting MIGS part accepted SION I for SAHARA to B could to behalf establish data discussion, from sales by efforts reimbursement a address our draft products. look on our American for SAHARA To of our MACs to and proposed patients LCDs surgical fee-for-service These annual OMNI treatments. key of Medicare TearCare of like recently CMS. forward discussing administer has fair with benefits begin for abstract impact Academy for in by glaucoma of patient its that results MACs Optometry the presentation at October. Phase the X and of been
demonstrating their all proven, surgeons' of glaucoma drafted. the least have the LCDs have treatments We considered patients publications. clinical as OMNI In for effective ability to implemented believe have flaws if these at particular, Medicare in numerous data, adversely proposals XX been peer-reviewed procedures, not would patients, serious currently proposed limit benefits published affect provide and which the and available
outcomes FDA data, the open-angle extensive adult and and glaucoma safe broad in real-world with label or clinical our effective reinforce POAG. patients primary Our OMNI use technology of
public important patients comment MACs to presentations importance help X OMNI to by Medical play critical continued the and trabeculotomy In of LCDs. LCDs. not technology, draft the hosted the our meetings considered the glaucoma benefits we overwhelming the the in regarding reiterated which to have provided technology our for physicians societies, clinical have OMNI open highlighted and at patients. of in expressing access of vision proposed was treatment nature open the These the POAG and meetings, role continued of the support MACs and additional access data, enabled preserve canaloplasty
XX two-year of OMNI further extension evidence mild-to-moderate data months. study and intraocular we medication This XX out of at OMNI the with the both reduction multicenter IOP of to results technology. months, we observed provides and from or longer-term demonstrated that ROMEO important efficacy glaucoma in our pressure POAG treated extended the This Study. our Specifically, presented durability patients originally use in
multicenter also combination OMNI XX-month We results surgery. our with of GEMINI, cataract from trial presented prospective in
months significantly met In studies. the GEMINI, at prespecified greater cataract usage to prospective and endpoint cataract the due reduction success with implant as to significant its historical the alone prespecified reduction medication control observed control. IOP GEMINI of The observed OMNI we surgery exceed in compared statistically the to the pivotal criteria successfully IOP study XX arm. reductions than with IOP historical control had MIGS in both arms efficacy
the crucial by POAG. MACs role other and the our that MACs efforts described of and necessary further plays all Our appreciate helped presentation the regarding positive in consistency technology of various the outcomes OMNI the who educate published societies the of the stakeholders highlighted observed patients, across the to We physicians, treatment and made articles.
implementation evidence, all the of for the criteria believe in We LCDs exceptional our these We market care specific favor clearance would superior response. benefits equivalent clinical or technology. to clinical accepted who the employees, OMNI published groups and proposed consensus also glaucoma are support they that access coordinated drafted, there therapy, based other like FDA particularly currently supportable clinical commercial by do to thank significant dedicated are coverage coverage clinical, of of continued as covered a and and which site all Medicare to enabled our standard is of procedures procedures, not guidelines, basis generally are on of
these and with almost news, other were preserve information believe we in options and pleased finalize or Cigna, either We We in maintain coverage lives, but the supporting June surgical as for clinical don't sufficient with report one by technology regarding patients. glaucoma procedures the this revised technology necessary to OMNI efficacy when United revise MACs insurance plan proposed the and our million States LCDs, largest visibility to of of importance covered real-world have to we to to to XX, covered provided procedures June the their for withdraw our appropriate include safety with OMNI-technology. continue at our POAG policy will performed of procedures XXXX. access that published all of enabled companies XX commercial as coverage medically coverage we results, communicate In and evidence stakeholders have to time as clinical OMNI to treatment and the continued their the health
This decision further validates OMNI's importance. clinical
market the record community. technology, the of as second our OMNI our exceeded bring overall our activity more benefits by business to our continued commercial quarterly to OMNI expectations. glaucoma adopted for surgical are quarter Commercially, as growth evidenced We excited Cigna MIGS revenue, the clinicians to the outpace
sticky, OMNI have Notably, the market a net that clear use despite was revenue access, and consistency via degree our proposed exceptional We continued to we retention of with to commercial who account strong the surgeons continues customer stability considerations efficacy OMNI associated base. technology, particularly our very positive. opportunity and excellence. our and expandable stable usability attribute this surgeon with from market current It's Feedback growing LCDs. the be stickiness its differentiated and of
of I XXXX the surgical to ophthalmic would congratulate and residents like fellows. class graduating
worked accounts of the with our strategic generation with latest improve over XXX forward to to lives surgeons of these has of surgeons to outstanding years partnering the new develop this patients using expertise with in hand-in-hand POAG Our look We come. to their technologies. team
OMNI stand-alone third-party expanded projected with claims provider, activity perform CPT analytics Based by a codes cataract stand-alone growth encouraged and within market accelerating measured expansion are segment, and associated the continues mix. OMNI. observed well the as penetration from stand-alone visits in data on the in by observing involving we to combo we we're patient
through While stand-alone field initiatives. ability cataract our procedure the combo development a to resources, and drive clinical to growth segment and remain education physician of modest targeted volumes and confident remain technology compared evidence, market program, leverages stand-alone comprehensive this segment, in in marketing awareness our patient comprehensive OMNI increasing which we
a seeking the in also The simpler to SION certain in addresses for the surgical portfolio, solution growth other of product SION, needs surgeons contributed our second quarter. MIGS patients. glaucoma our
is for to with industry it pleased positive the total contributor are still overall a reception We although revenue. small SION,
business. causes address and have disease MGD, for of MGD. do been Historically, TearCare underlying unmet which needs eye meibomian We drops, our XX% and of of which evaporative gland Turning treatment eye dry with eye technology associated not to dry cases. has the designed artificial by dry our eye is prescription dry of dominated up or to the eye address to tears and with clinical both limitations patients serious
treatment believe the X technology results TearCare in demonstrate should role our play in SAHARA that We observed prominent the Phase eye a dry paradigm.
self-pay launch, procedure treatment commercial relief a controlled illustrating MGD. growing adoption we experienced can a option, our from the pent-up safe TearCare that for as of offer During and effective demand have
believe with reimbursement. our for is immense appropriate and potential We fair there technology TearCare
between RCT, using its Restasis procedures and over daily at our key drop of stability retention, film's and improving In tear sites prescription of thrilled states primary a TearCare SAHARA, science are of its groups. measure ability the by the up the achieved eye of SAHARA We the the treatment demonstrating Restasis six-month drug, to XX enabled endpoint, tear trial, randomized treatments device patients clinical in first were interventional superiority TearCare time, Restasis. aqueous this XXX TearCare comparing ocular to surface. protect eyedrops kind use head-to-head of technology by tear-break and eyelid XX first X:X success with twice
the procedures interventional and ensure results, payer months. Throughout SAHARA endpoints and improvements to three TearCare study, that discussions. evaluated measurement week, demonstrated one month, to successful, to coverage XX months designed provide bias RCT if healthy the significant exacting interval six eyelid every would meaningful support potential We statistically date, standards clinically with of minimize all at for the and with one
in to six assessors potential rather treatment bias. three than carried These Endpoint Restasis assignment by endpoint out common has setting time reach to We months period or ensure sufficient the did to measures were superiority one minimize included assessments masked months further help the dry intentionally eye studies. at to peak effect. this
with from the SAHARA plan coordination principal leading we journals. study's In results investigators, X Phase to submit peer-reviewed to
and economics patient impact treatment with model believe of persuasive published, and research these health associated to evidence payers the we support outcomes disease revamp provide doctors access and We a will preparing If are dry successfully also reimbursement. articles eye and for encourage publication. budget to
access advancing To the the date, technology now commitment the clinical our to investigators exceptional team, ability for comprehensively in user-friendly believe TearCare outcomes and this cause lives chronic at to our rigorous efforts expanding MGD improving involved dry RCTs. received results. suffering procedures SAHARA of with and the recognize like diseases. intervene all TearCare the best-in-class was The in payers has pleased to produce patients and provides. our technology consistently trial. way two OMNI rigorous of designed look market RCT SAHARA from usage we highlights I very root to clinical clinical with of to the and our of We patients forward are strategy, team the evidence, demonstrated a eye have of that data we important not eye would our
will to call over I discuss financials. now turn to our Ali the
